Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
JAxe,
Cupid’s arrows might be sharp,
But my love for you is off the (share price) chart.
Happy Valentine's day
x x x
Here's another view then; your guesstimate is wildly over-stated. Remember the company have said they are doing "small, focussed" stratified studies, not more 'Sprinter trials'. So perhaps you have based your figs on incorrect assumptions.
Mani has purposefully omitted the other significant changes mentioned on page 9 pf the Financial Report to make the financials look weaker. In the Statement of Financial Position, we now have current tax receivable of £2.4 million, and trade and other payables decreased to £3.3 million (as trade payables reduced from £4.2 million to £0.5 million in line with the reduction in the level of operating expenditure).
Mani has not included these changes in her wild guesstimate. Only an idiot, etc....
Share alledgedly worth "5p" is the subject of totally random (yet recurrent) postings by alleged "party planner" jAxe, who for some reason can't stop coming back to post about a stock he thinks is totally worthless.
lol
"I have laid out in an earlier post the numbers here just do not add up, and it is difficult to see where"
Perhaps if you were an accountant the numbers would add up. That, and using verified numbers instead of made up ones, would help.
Bore off Prof.
Spaceman quotes a decade old report based on US costings. Read the fine print. Wildly inaccurate by any measure, given the efficiencies gained in the past number of years, and no doubt another desperate attempt to erode shareholder confidence.
I think Spaceman needs to have a word with our new CFO Mr. Colliver . He who said “This is a pivotal time for the Company, as it works towards the next phase of clinical trials with SNG001. I look forward to working closely with Richard and the team in the coming months and years.” Years. As in multiple. As in, no funding issues to fret about, kind of thing....
I could be wrong, but I imagine Mr.Colliver really does know more than Spaceman, both about the company's finances, and their plans, when he made that deliberate and inightful statement.
...but he's a Financial professional, @TommyD_19, don't you know.
Lol
Yup, another Broken Record.
In other news though, the new CMO and CFO, fully onboarded in November, are busy launching us into the next phase.
And the Olivetti.
I still have great difficulty imagining the mutterings of the company bankers and advisors present when Ghia's "offer to fund a P3" (lol) was was, ahem, politely declined... Indeed. To have been a fly on the wall. The entertainment value of that alleged scenario is up there with the best of them, vying for a place in the Hall of Fictional Fame...
Another obvious reason for Radio Silence; diligence process in progress. Rigidly worded email responses. Same message. No word from FC. No word from new CMO. No conferences. No interviews. No random posting activity on LI, X, etc. It fits with the less frequent comms. It will also be out of the company's control if that is happening - the other party (or parties) would probably have stipulated only the most stringent and bare-minimum comms to be made whilst dd in process if it is.
The other possible reason is that the CMO is deep in action with the Regulator(s). This has already been communicated to investors as part of the next steps.
A final observation prompted by Doc.Dan's comment below (" they didn't even tell us where they were trialing."). Indeed. Thought provoking. So why expect a change in tack now...?
Last thing, i'd tick 1-4 on your list below DocDan. The CMO should be working on #5 already.
LOL
LOL
"What kind of reaction is there in the BP world, on whom we are totally dependent, when a known "voice" like Brooke Clarke is allowed to leave"
lol.
I think you are conflating current circumstances with an overly-dramatic episode of Neighbours circa 1997.
You haven't noticed it TP...?
It would be nice but I don't see the value in vague updates, particularly with the SP so open to abusive manoeuvres. The less they say the better until there is something very concrete to report. They are under no obligation to provide operational updates in the meantime, although I suppose one could view latest email response (see below) as ticking that box:
"Many thanks for your recent enquiry. Synairgen is progressing its plans, based on insights from non-interventional studies, to assess SNG001 in target patient groups with the highest needs. You can expect announcements when substantive milestones are reached, and as per the financial calendar, with full year results for 2023 due to be reported in Q2."
I feel a bit late to the party on this one (proof if ever it was needed that I am not in fact RM or one of his minions, lol!).
Anyway, you can look at this covert hire a number of ways, I find all of these to be positive to getting us where we need to be. It is:
- a sign of growth and expansion - self explanatory what is coming, i.e. growth and expansion!....
- a sign that funds will need to be raised - a financial controller can provide accurate financial data to potential investors
- a sign that trials are surely coming, perhaps rubber stamped now by some regulatory green flag? Financial controllers play a critical role in managing budgets for clinical trials because they track expenses related to research, development, and regulatory compliance.
- A sign of due diligence on the horizon. When mergers, acquisitions, or licensing agreements are being considered, a financial controller ensures thorough due diligence in the process.
- A financial controller ensures compliance with financial regulations, (local) tax laws, and reporting requirements, particularly important when scaling up with a foreign element...
We don't know which of these applies here, but what is clear is that hiring a financial controller should always align with a company’s growth stage, financial needs, and strategic goals. This hire in November 23 is an indication IMO that we are without doubt moving to the next level.
Nobody "lost" anything. Funds get 'spent''.
And just to add, there was no mystery in John Ward's departure:
"owing nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO and Executive Director on Friday 3 November.
Richard Marsden, CEO of Synairgen, said: "Joseph's many years of listed company experience, including in the healthcare sector, will stand us in good stead as we progress towards the clinic with our SNG001 strategy. I'd like to thank John for his steadfast commitment, loyalty and support to both me and the Board over many years. We wish him the very best for the future." Joseph Colliver, newly appointed CFO of Synairgen, commented: "This is a pivotal time for the Company, as it works towards the next phase of clinical trials with SNG001. I look forward to working closely with Richard and the team in the coming months and years." John Ward, outgoing CFO of Synairgen, commented: "It has been a pleasure to work with the Synairgen team for these many years, driven by the shared vision to develop treatments for severe viral lung infections. However, it's the right time to pass on the baton, and I look forward to following the Company's next steps and wish the team every success with SNG001 in the future."
Still, your fictional version of events was entertaining, if not wholly expected Ms. Mani.